比卡鲁胺联合重组人瘦素拮抗剂对前列腺癌DU-145细胞增殖及凋亡的影响

摘要

Objective To study the effect of bicalutamide combined with recombinant human leptin antagonists on proliferation and apoptosis of prostate cancer cell line DU-145,which will provide theoretical basis for the clinical treatment of prostate cancer.Methods After being induced in vitro by recombinant human leptin,DU-145 cells were treated respectively by bicalutamide (with a concentration of 1,2,5,10 μ mol/L),recombinant human leptin antagonist(with a concentration of 5,10,20,50 ng/mL),and their combination (with a concentration of 5 μ mol/L,20 ng/mL) for 24 hours.The proliferation inhibition and apoptosis rates of the treated cells were measured by methyl thiazolyl tetrazolium (MTT) assay and flow cytometry (FCM).Results The proliferation of DU-145 cells was significant inhibited and the apoptosis of DU-145 cells was significantly induced under the treatment of bicalutamide and recombinant human leptin antagonist alone,as well as their combination.The proliferation inhibition and apoptosis rates of the treated cells in the combined treatment group were obviously higher than those in other alone groups (P ＜ 0.05).Conclusion Bicalutamide and recombinant human leptin antagonist could inhibit the proliferation of DU-145 cells,induce the apoptosis; and combined application of the two has a synergistic effect.%目的 为比卡鲁胺联合重组人瘦素拮抗剂治疗对前列腺癌提供理论依据.方法 重组人瘦素诱导体外培养DU-145细胞后,分别采用1、2、5、10 μmol/L浓度的比卡鲁胺,5、10、20、50 ng/mL浓度的重组人瘦素拮抗剂及二者联合应用(浓度分别为5 μmol/L、20 ng/mL)干预24h.采用MTT法检测细胞增殖抑制率,流式细胞仪检测细胞凋亡率.结果 各浓度比卡鲁胺、重组人瘦素拮抗剂及二者联合应用均能显著抑制DU-145细胞增殖,诱导其凋亡；二者联合应用的细胞增殖抑制率、细胞凋亡率均明显高于相同浓度的比卡鲁胺和重组人瘦素拮抗剂单用；P均＜0.05.结论 比卡鲁胺和重组人瘦素拮抗剂均可抑制DU-145细胞增殖,诱导其凋亡；二者联合应用有协同作用.